# Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study

> **NCT04462965** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 294 (estimated)

## Conditions studied

- Mucosal Melanoma

## Interventions

- **COMBINATION_PRODUCT:** Toripalimab
- **COMBINATION_PRODUCT:** Temozolomide

## Key facts

- **NCT ID:** NCT04462965
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-30
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04462965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04462965, "Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04462965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*